Pharmacological evaluation of aerosolized cannabinoids in mice

European Journal of Pharmacology

Volumn 399, Issue 2-3, 2000, Pages 141-149

  Lichtman, Aron H ^a   Peart, Joanne ^a   Poklis, Justin L ^a   Bridgen, D Troy ^c   Razdan, Raj K ^b   Wilson, David M ^a   Poklis, Alphonse ^a   Meng, Yun ^a   Byron, Peter R ^a   Martin, Billy R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ORGANIX INC   (United States)

^c NONE

Author keywords

9 THC ( 9 tetrahydrocannabinol); Aerosol; Antinociception; Cannabinoid; Marijuana; medical; Nebulizer; SR 141716A

Indexed keywords

CANNABINOID; CANNABIS; DELTA9(11) TETRAHYDROCANNABINOL; RIMONABANT;

AEROSOL; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; EXPOSURE; MALE; MOUSE; NEBULIZER; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; PAIN; PIPERIDINES; PYRAZOLES; TETRAHYDROCANNABINOL;

EID: 0034617372     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00321-6     Document Type: Article

References (52)

1. Anderson P.J., Wilson J.D., Hiller F.C. Particle size distribution of mainstream tobacco and marijuana smoke. Analysis using the electrical aerosol analyzer. Am. Rev. Respir. Dis. 140:1989;202-205.
2. Beal J.E., Olson R., Laubenstein L., Morales J.O., Bellman B., Yangco B., Lefkowitz L., Plasse T.F., Shepard K.V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10:1995;89-97.
3. Beal J.A., Olson R., Lefkowitz L., Laubenstein L., Bellman P., Yangco B., Morales J.O., Murphy R., Powderly W., Plasse T.F., Mosdell K.W., Shepard K.W. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J. Pain Symptom Manage. 14:1997;7-14.
4. Bliss C.I. Statistics in Biology. 1967;439 McGraw-Hill, New York.
5. Byron P.R. Pulmonary targeting with aerosols. Pharm. Technol. 11:1987;42-56.
6. 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 263:1992;1118-1126.
7. Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharmacol. Exp. Ther. 260:1992;201-209.
8. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
9. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
10. Dewey W.L., Harris L.S., Howes J.F., Nuite J.A. The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests. J. Pharmacol. Exp. Ther. 175:1970;435-442.
11. 9-THC, CP 55,940 and WIN 55,212. J. Pharmacol. Exp. Ther. 271:1994;1383-1390.
12. Ferri S., Cavicchini E., Romualdi P., Speroni E., Murari G. Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology. 89:1986;244-247.
13. Foltz R.L., Fentiman A.F., Foltz R.B. GC/MS Assays for Abused Drugs in Body Fluids. NIDA Res. Monogr. 1980;202 US Govt. Printing Office, Washington, DC. Vol. Series #32.
14. Frytak S., Moertel C.G., O'Fallon J.R., Rubin J., Creagan E.T., O'Connell M.J., Schutt A.J., Schwartau N.W. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann. Intern. Med. 91:1979;825-830.
15. 9-tetrahydrocannabinol. J. Pharm. Sci. 63:1974;1056-1064.
16. Hartley J.P., Nogrady S.G., Seaton A. Bronchodilator effect of delta1-tetrahydrocannabinol. Br. J. Clin. Pharmacol. 5:1978;523-525.
17. 9-tetrahydrocannabinol content. Fundam. Appl. Toxicol. 4:1984;451-454.
18. Hinds W.C. Aerosol Technology: Properties, Behaviour and Measurement of Airbourne Particles. 1982;Wiley-Interscience, New York.
19. 9-tetrahydrocannabinol reflect the degree of intoxication? J. Clin. Pharmacol. 21:1981;171S-177S.
20. Huber G.L., Pochay V.E., Pereira W., Shea J.W., Hinds W.C., First M.W., Sornberger G.C. Marijuana, tetrahydrocannabinol, and pulmonary antibacterial defenses. Chest. 77:1980;403-410.
21. Johnston L.D., O'Malley P.M., Bachman J.G. National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1997: vol. 1. Secondary School Students. 1998;National Institute on Drug Abuse, Rockville, MD. (NIH Publication No. 98-4345).
22. Johnston L.D., O'Malley P.M., Bachman J.G. National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1997: vol. 2: College Students and Young Adults. 1998;National Institute on Drug Abuse, Rockville, MD. (NIH Publication No. 98-4346).
23. Joy J.E., Watson S.J., Benson J.A. Marijuana and Medicine - Assessing the Science Base. 1999;. Institute of Medicine.
24. Lee M.L., Novotny M., Bartle K.D. Gas chromatography/mass spectrometric and nuclear magnetic resonance spectrometric studies of carcinogenic polynuclear aromatic hydrocarbons in tobacco and marijuana smoke condensates. Anal. Chem. 48:1976;405-416.
25. Lemberger L. Tetrahydrocannabinol metabolism in man. Drug Metab. Dispos. 1:1973;461-468.
26. Lichtman A.H., Smith F.L., Martin B.R. Evidence that the antinociceptive tail-flick response is produced independently from changes in either tail-skin temperature or core temperature. Pain. 55:1993;283-295.
27. Lichtman A.H., Meng Y., Martin B.R. Inhalation exposure to volatilized opiates produces antinociception in mice. J. Pharmacol. Exp. Ther. 279:1996;69-76.
28. Lichtman, A.H., Poklis, J.L., Poklis, A., Wilson, D.M., Martin, B.R., in press. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug Alcohol Depend.
29. Little P.J., Compton D.R., Johnson M.R., Melvin L.S., Martin B.R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247:1988;1046-1051.
30. Martin B.R. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci. 36:1985;1523-1530.
31. Martin, B.R., Razdan, R.K., 1998. Water soluble derivatives of cannabinoids. United States Patent Number 5,847,128.
32. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
33. O'Shaughnessy W.B. On the preparation of Indian hemp and gunjah. Trans. Med. Phys. Soc. Bombay. 8:1842;421-461.
34. Ohlsson A., Lindgren J.-E., Wahlen A., Agurell S., Hollister L.E., Gillespie H.K. Plasma delta-9-tetrahydrocannabinol concentrations and effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28:1980;409-416.
35. 9-tetrahydrocannabinol for intravenous injection. J. Pharm. Pharmacol. 25:1973;344.
36. Pertwee R., Gibson T.M., Stevenson L.A., Ross R.A., Banner W.K., Saha B., Razdan R.K., Martin B.R. Br. J. Pharmacol. 129:2000;. in press.
37. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
38. 9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293:1975;795-797.
39. 9-tetrahydrocannabinol and prochlorperazine. N. Engl. J. Med. 302:1980;135-138.
40. Schlesinger R.B. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J. Toxicol. Environ. Health. 15:1985;197-214.
41. Schwartz R., Voth E. Marijuana as Medicine: making a silk purse out of a sow's ear. J. Addict. Med. 14:1995;15-21.
42. Stiefel F. U.S.: marihuana for cancer-related symptoms. Support Care Cancer. 4:1996;76.
43. Tashkin D.P., Shapiro B.J., Reiss S., Olsen J.L., Lodge J.W. Bronchial effects of aerosolized delta-9-tetrahydrocannabinol. Cohen S., Stillman R.C. The Therapeutic Potential of Marihuana. 1976;97-109 Plenum, New York.
44. Tashkin d., Reiss S., Shapiro B., Calvarese B., Olsen J., Lodge J. Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects. Am. Rev. Respir. Dis. 115:1977;57-65.
45. Taylor H.G. Analysis of the medical use of marijuana and its societal implications. J. Am. Pharm. Assoc. 38:1998;220-227.
46. Vachon L., Robins A., Gaensler E.A. Airways response to aerosolized delta-9-tetrahydrocannabinol: preliminary report. Cohen S., Stillman R.C. The Therapeutic Potential of Marihuana. 1976;111-121 Plenum, New York.
47. Voth E., Schwartz R. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann. Intern. Med. 126:1997;791-798.
48. 9-tetrahydrocannabinol and related cannabinoids in man. J. Clin. Pharmacol. 21:1981;178S-189S.
49. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception following intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
50. Williams S.J., Hartley J.P., Graham J.D. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax. 6:1976;720-723.
51. Wu T., Tashkin D.P., Djahed B., Rose J.E. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 318:1988;347-351.
52. Yaksh T.L. The antinociceptive effects of intrathecally-administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;3345-3405.